The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

This study has been completed.
Sponsor:
Information provided by:
Gachon University Gil Medical Center
ClinicalTrials.gov Identifier:
NCT01283958
First received: January 25, 2011
Last updated: NA
Last verified: May 2010
History: No changes posted
  Purpose

Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.


Condition
Eisenmenger's Syndrome

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Resource links provided by NLM:


Further study details as provided by Gachon University Gil Medical Center:

Enrollment: 12
Study Start Date: September 2007
Study Completion Date: May 2010
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

12 patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization

Criteria

Inclusion Criteria:

  • patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization

Exclusion Criteria:

  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Song I Yang, Gil Hospital, Gachon University of Medicine
ClinicalTrials.gov Identifier: NCT01283958     History of Changes
Other Study ID Numbers: no sponsor
Study First Received: January 25, 2011
Last Updated: January 25, 2011
Health Authority: Korea: Institutional Review Board

Keywords provided by Gachon University Gil Medical Center:
Iloprost, Eisenmenger's syndrome

Additional relevant MeSH terms:
Eisenmenger Complex
Heart Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Congenital Abnormalities
Iloprost
Platelet Aggregation Inhibitors
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Vasodilator Agents
Cardiovascular Agents

ClinicalTrials.gov processed this record on April 23, 2014